Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.10.004
Abstract: Nivolumab-ipilimumab has become the standard of care in the frontline setting for intermediate-/poor-risk metastatic renal cell carcinoma (mRCC). This regimen is associated with survival improvement but significant toxicity. Anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)… read more here.
Keywords: renal cell; analysis; ipilimumab; prior anti ... See more keywords
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01365-y
Abstract: Dear Editor, Even at the era of T-cell redirecting therapies, patients with relapsed or refractory multiple myeloma (RRMM) presenting extramedullary disease (EMD) and/or high risk cytogenetic abnormalities (HRCA) constitute a particularly challenging sub-group with lower… read more here.
Keywords: prior anti; anti bcma; rrmm; bcma cd3 ... See more keywords
A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.5540
Abstract: 5540 Background: Clinical findings on onatasertib (ATG-008), an oral TORC1/2 inhibitor, showed promising anti-tumor efficacy and manageable safety when used in combination with toripalimab, an anti-PD-1 monoclonal antibody, in treatment-naïve cervical cancer (CC) patients who… read more here.
Keywords: prior anti; therapy; combination; anti therapy ... See more keywords
7250 Effects of Romosozumab According To Prior Anti-Resorptive Treatments In Korean Postmenopausal Women From The Real-World Data: A Multi-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvae163.412
Abstract: Abstract Disclosure: Y. Kim: None. S. Ahn: None. S. Lee: None. S. Lee: None. H. Kim: None. S. Hong: None. Objectives: This study investigated the effects of romosozumab in Korean postmenopausal women based on their… read more here.
Keywords: anti resorptive; prior anti; none; postmenopausal women ... See more keywords
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1527102
Abstract: Introduction Anti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support… read more here.
Keywords: prior anti; monoclonal antibody; anti cd20; therapy ... See more keywords
The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.
Sign Up to like & getrecommendations! Published in 2025 at "Intestinal research"
DOI: 10.5217/ir.2024.00126
Abstract: Background/Aims Previous literature suggests that the response of patients with ulcerative colitis to vedolizumab may be affected by previous biologic therapy exposure. This real-world study evaluated vedolizumab treatment effectiveness in biologicnon- naïve patients. Methods This… read more here.
Keywords: prior anti; duration prior; vedolizumab; ulcerative colitis ... See more keywords